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Age, Cohort-of-Birth, and
Period-of-Death Trends in
Breast Cancer Mortality
in Europe
An age-period and cohort model fit to
breast cancer mortality data in the
United States and Canada showed
downward shifts in slopes of cohort ef-
fects for white women born after 1925
and for period-of-death values from
1970 onward (1).
We applied an age-period and cohort
model to European breast cancer mor-
tality data. Briefly, official cancer death
certification numbers for 16 major Eu-
ropean countries during the period
1955-1994 were derived from the World
Health Organization (WHO) database
(2). Estimates of the resident population,
generally based on official censuses,
were obtained from the same WHO da-
tabase. From these data, age-specific
death certification rates for each 5-year
calendar period and age group (from 30-
34 years to 75-79 years) were derived.
From the matrices of age-specific
death rates, the effects of age, cohort of
birth, and period of death were esti-
mated through a log-linear Poisson
model, fitted using GLIM with appropri-
ate user-supplied macros (3). In simpli-
fied terms, the estimates presented are
derived from the model including the
three factors (age, cohort, and period),
which minimizes the sum of the Euclid-
ean distances from the three possible
two-factor models (age and period, age
and cohort, or cohort and period). The
procedure is conceptually similar to that
described by Osmond and Gardner (4).
The age values are interpretable in terms
of mean age-specific death rates in the
period considered. Cohort and period-
of-death values were averaged to unity.
Cohort values related to earlier and
more recent periods are based on fewer
age-specific rates and, hence, are less
reliable than central ones.
Fig. 1 gives the age, cohort, and pe-
riod values for breast cancer mortality in
the 16 major European countries consid-
Fig. 1 (see facing page also). Age, co-
hort, and period effects for breast can-
cer mortality in women in selected Eu-
ropean countries. The age effect can be
interpreted in terms of rates per
100 000 population. Cohort and period-
of-death effects are expressed in rela-
tive terms against their weighted aver-
age set to unity.
CORRESPONDENCE Journal of the National Cancer Institute, Vol. 89, No. 10, May 21, 1997732
ered. Age values tended to be higher in
northern Europe and lower in southern
and eastern European countries. Cohort
values showed two patterns, since most
northern European countries showed no
noteworthy trend, while there were ap-
preciable increases for cohort values in
Spain, Portugal, Greece, Hungary, and
Poland as well as a small increase in
Italy. Period-of-death values were stable
in most countries.
It seems, therefore, that subsequent
generations of women from originally
low-risk European countries had experi-
enced increased breast cancer mortality,
thus leading to a leveling of breast can-
cer death rates across Europe. This find-
ing probably reflects more uniform re-
productive, hormonal, and perhaps
dietary factor exposures among younger
women in various European countries
(2,5,6).
These figures are not directly compa-
rable to those given by the model ap-
plied by Tarone et al. (1), which consid-
ered changes in slopes. In terms of
changes in slopes, several European
countries showed downward shifts for
most recent generations, and some of
them, including the largest ones (i.e.,
France, Germany, Italy, and the U.K.),
also showed downward shifts for most
recent periods of death.
Nonetheless, the fall in breast cancer
rates observed over recent calendar pe-
riods and cohort of births in North
American white women (1) was only
partly reproduced in Europe. This result
suggests that there are differences and
specificities in reproductive variables
and exposures to other likely risk fac-
tors, as well as in early diagnosis (7) and
management of the disease, in various
developed areas of the world. Further-
more, an appreciable heterogeneity was
observed in breast cancer mortality
across various European countries and
geographic areas (6,8), whose determi-
nants should be further investigated.
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Re: Monitoring of Aromatic
Amine Exposures in Workers
at a Chemical Plant With a
Known Bladder Cancer Excess
In 1991, investigators from the Na-
tional Institute for Occupational Safety
and Health (NIOSH) (1) reported a cor-
relation between o-toluidine and aniline
exposure and an increased incidence of
bladder cancer. Letters published in the
Journal (2-4) identified deficiencies and
inaccuracies in the study. The recent ar-
ticle by investigators from NIOSH (5)
continues the inaccurate portrayal of o-
toluidine and aniline as human bladder
carcinogens.
The bladder cancers were diagnosed
in the early 1980s. Since the latent pe-
riod between exposure and tumor ex-
pression averages about 20 years,
NIOSH should have examined worker
exposure to chemicals used in the early
1960s, but it did not do so. The article
(5) states, ‘‘There were insufficient his-
torical data to characterize exposures at
the plant 10-30 years ago, the time pe-
riod most relevant to the development of
industrially related bladder cancers,
which have a latent period . . . averaging
20 years. . . .’’ Therefore, NIOSH ad-
mits it has no knowledge of the specific
chemicals to which the affected workers
were exposed. NIOSH also admits that
exposures 10-30 years ago are most rel-
evant to causation but ignores historical
exposure information.
There is documentation that workers
were exposed in the 1950s and early
1960s to diphenylamine. Diphenylamine
often contained 4-aminobiphenyl, a
known human bladder carcinogen (6).
NIOSH admits the possibility of expo-
sure to 4-aminobiphenyl from contact
with process chemicals but dismisses
4-aminobiphenyl as a causative agent.
Donald Sherman, M.D., Corporate
Medical Director for the affected plant,
informed NIOSH that 4-aminobiphenyl
was present in the plant from 1957 to
mid-1966. He stated that no worker with
a start date after 1966 has developed
bladder cancer. Dr. Sherman states,
‘‘We have believed all along that aniline
and o-toluidine did not cause the cancers
in the Niagara Falls plant. . . . The expo-
sures to aniline and o-toluidine from
1966 to the late 1970s did not change
significantly, based upon process design
and configuration. If o-toluidine was the
real culprit . . . would we not have seen
more bladder cancers? . . . We believe
the probable cause was 4-aminobiphe-
nyl. . . .’’ (Sherman DJ: personal com-
munication to Ward JM, May 23, 1996).
This confirmation that workers with
bladder cancer were exposed to 4-ami-
nobiphenyl invalidates the conclusions
of the NIOSH study that used exposure
data from the late 1980s.
NIOSH reported workplace air con-
centrations of 187 and 412 mg/m3 for
aniline and o-toluidine, respectively, or-
ders of magnitude below the Occupa-
tional Safety and Health Administration
Permissible Exposure Limits (PELs) of
8000 and 22 000 mg/m3 and the Ameri-
can Conference of Governmental Indus-
trial Hygienists (ACGIH) Threshold
Limit Values (TLVs) of 7600 and 8800
mg/m3, the concentrations to which
workers can be exposed 8 hours per day,
5 days per week, for 30 years without
adverse health effects. Furthermore, in
1996, the ACGIH downgraded the clas-
sification of aniline and o-toluidine from
‘‘suspected human carcinogen’’ to
‘‘animal carcinogen.’’ NIOSH appar-
ently refutes the validity of TLVs and
PELs as universally accepted safe expo-
sure levels.
There are no data in Ward et al. (5)
that support the NIOSH conclusion that
‘‘. . . occupational exposure to o-tolu-
idine is the most likely cause of the blad-
der cancer excess observed among
workers in the . . . plant under
study. . . .’’
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Ward et al. (1) recently presented the
results of biologic monitoring of work-
ers for aromatic amine exposure in a
chemical plant. They concluded that ex-
posure to o-toluidine is the most likely
cause of the excess numbers of bladder
cancers found in the study population
and noted that exposure to aniline can-
not be ruled out as a potential cause.
This article follows an earlier study in
which they found an excess of bladder
cancer at the plant (2).
Several articles (3-8) have linked
source of drinking water, total fluid in-
take, water disinfection methods, or ex-
posure to chlorinated surface water with
bladder cancer. Four of these articles (5-
8) were published before Ward et al.
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